Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06473766 | Ultrasound RF Data for Discriminating Between Benign and Malignant Ovarian Masses(RFDATA) | unknown | N/A | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06440018 | INSPIRE: a Multi-Cancer Early Detection Study(INSPIRE) | unknown | — | 5,350 | Singlera Genomics Inc.INDUSTRY | 1 |
| Feb 21, 2025 |
| clinicaltrials |
| NCT06566716 | A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass | unknown | — | 1,000 | Cleo Diagnostics LtdINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06541314 | Fluzoparib Neoadjuvant Therapy for Ovarian Cancer | unknown | Phase 2 | 48 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT05099978 | Asian Multicenter Prospective Study of ctDNA Sequencing(A-TRAIN) | unknown | — | 506 | National Cancer Center, JapanOTHER_GOV | 8 | Sep 4, 2024 | clinicaltrials |
| NCT06574763 | Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT05475184 | A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor | unknown | Phase 2 | 58 | Onconic Therapeutics Inc.INDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05684731 | Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer(K19017-004) | unknown | Phase 1 | 30 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05025878 | 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.(iMETABO) | unknown | — | 10 | British Columbia Cancer AgencyOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04787289 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | unknown | Phase 2 | 244 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02991677 | Exercise Effect on Chemotherapy-Induced Neuropathic Pain | unknown | N/A | 60 | Baltimore VA Medical CenterFED | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06533709 | Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data | unknown | — | 146 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06515678 | Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension(IATRO) | unknown | — | 9,464 | Groupe Hospitalier Pitie-SalpetriereOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03614689 | Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire | unknown | — | 104 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05610501 | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. | unknown | — | 200 | Universitaire Ziekenhuizen KU LeuvenOTHER | 4 | Jul 3, 2024 | clinicaltrials |
| NCT06468254 | An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer | unknown | Phase 2 | 500 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06018935 | A Cohort Establishment Study of Total Management of Ovarian Cancer | unknown | — | 500 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06445621 | Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test(FOLL-OV) | unknown | — | 125 | Uppsala University HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06377267 | Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)(STROBE) | unknown | Phase 2 | 100 | Vall d'Hebron Institute of OncologyOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT02296307 | DOvEE - Diagnosing Ovarian & Endometrial Cancer Early(DOvEE) | unknown | — | 13,600 | McGill UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05989724 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 150 | Qurgen Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06376604 | Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies | unknown | N/A | 30 | L-Nutra IncINDUSTRY | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05748353 | Endocrine Disruptors and Life STILe in Breast Cancer Development(STILVARCA) | unknown | — | 275 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05848648 | PPK Study Based on Quantitative Pharmacology in Patients With Pamipril | unknown | — | 50 | Qianfoshan HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05305820 | Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy(PANO) | unknown | N/A | 36 | Dublin City UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06320418 | The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression | unknown | — | 56 | Ain Shams UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06317610 | Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids | unknown | — | 100 | Chongqing University Cancer HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06304922 | BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary | unknown | — | 45 | Assiut UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06277947 | Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward(GARD-HIPEC) | unknown | N/A | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04145388 | Family History Study on Cancer Risk | unknown | N/A | 18,623 | Kaiser PermanenteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06250686 | Exercise and Nutrition Intervention in Ovarian Cancer(BENITA) | unknown | N/A | 185 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06243185 | Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors | unknown | Phase 2 | 30 | Fengzhi FengOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241105 | Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 69 | Peking Union Medical College HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06242392 | The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer | unknown | — | 250 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 5, 2024 | clinicaltrials |
| NCT06238284 | HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China | unknown | — | 300 | Chongqing University Cancer HospitalOTHER | 0 | Feb 2, 2024 | clinicaltrials |
| NCT05212779 | Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease | unknown | — | 45 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06236958 | Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer Patients | unknown | — | 200 | Luo ChengyanOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04470921 | STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands(STOPOVCA) | unknown | — | 10,000 | Radboud University Medical CenterOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05489926 | A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure | unknown | Phase 2 | 15 | Zhejiang Cancer HospitalOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05738902 | Adherence and Compliance to ERAS in Gynecological Surgery(ERASGYNBS002) | unknown | — | 600 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Jan 25, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2025source: clinicaltrials